Literature DB >> 30947660

Identification of Genes Associated with Lung Adenocarcinoma Prognosis.

Zhe-Hao He1, Wang Lv1, Lu-Ming Wang1, Yi-Qing Wang1, Jian Hu1.   

Abstract

OBJECTIVE: Lung cancer is the most prevalent cancer in the world, and lung adenocarcinoma is the most common lung cancer subtype. Identification and determination of relevant prognostic markers are the key steps to personalized cancer management.
METHODS: We collected the gene expression profiles from 265 tumor tissues of stage I patients from The Cancer Genome Atlas (TCGA) databases. Using Cox regression model, we evaluated the association between gene expression and the overall survival time of patients adjusting for gender and age at initial pathologic diagnosis.
RESULTS: Age at initial pathologic diagnosis was identified to be associated with the survival, while gender was not. We identified that 15 genes were significantly associated with overall survival time of patients (FDR < 0.1). The 15-mRNA signature- based risk score was helpful to distinguish patients of high-risk group from patients of low-risk group.
CONCLUSION: Our findings reveal novel genes associated with lung adenocarcinoma survival and extend our understanding of how gene expression contributes to lung adenocarcinoma survival. These results are helpful for the prediction of the prognosis and personalized cancer management. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Lung adenocarcinoma; cancer management; gene; lung cancer; markers; prognosis.

Year:  2019        PMID: 30947660     DOI: 10.2174/1386207322666190404152140

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  1 in total

1.  Overexpressed transient receptor potential vanilloid 1 (TRPV1) in lung adenocarcinoma harbours a new opportunity for therapeutic targeting.

Authors:  Yichu Nie; Fenglan Feng; Wei Luo; Andrew J Sanders; Yidi Zhang; Jiaming Liang; Cheng Chen; Weineng Feng; Weiquan Gu; Weiping Liao; Wei Wang; Jinfeng Chen; Lijian Zhang; Wen G Jiang; Jin Li
Journal:  Cancer Gene Ther       Date:  2022-03-30       Impact factor: 5.854

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.